NCT05904730 is a Phase 1 clinical trial of Axitinib in Breast Cancer, sponsored by Lynkcell Europe.

Who is sponsoring NCT05904730?

NCT05904730 is sponsored by Lynkcell Europe.

What drugs are being tested in NCT05904730?

Interventions in NCT05904730: Axitinib.

What condition does NCT05904730 study?

NCT05904730 studies Breast Cancer, Ovarian Cancer, Breast Neoplasms, Ovarian Neoplasms, BRCA Mutation, HER2-positive Breast Cancer, HER2-negative Breast Cancer, HER-2 Protein Overexpression.

Is NCT05904730 still recruiting?

NCT05904730 is currently completed. Last updated 30 December 2024.

Last reviewed 2024-12-30 · How we verify

NCT05904730

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Completed Phase 1 Last updated 30 December 2024

What this trial tests

Phase 1 trial testing Axitinib in Breast Cancer in 10 participants. Completed in 26 December 2024.

Timeline

11 July 2023

Primary endpoint
9 November 2024

26 December 2024

Quick facts

Lead sponsor	Lynkcell Europe
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	11 July 2023
Primary completion	9 November 2024
Estimated completion	26 December 2024
Sites	2 locations across Ukraine

Drugs / interventions tested

Axitinib — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Ovarian Cancer — all drugs for Ovarian Cancer →
Breast Neoplasms — all drugs for Breast Neoplasms →
Ovarian Neoplasms — all drugs for Ovarian Neoplasms →

Sponsor

Lynkcell Europe

Who can join

18 and older, any sex, with Breast Cancer or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Clinical Trial is investigating the potential efficacy of axitinib after genetic testing in BRCA 1/2 Mutation patients, regardless of HER2 expression, who have progressed after at least one line of standard treatment or for whom there is no consensus treatment approach. The use of Axitinib may help physicians plan for more effective patient care in combination with existing treatment protocols.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Obesity and leptin in breast cancer angiogenesis.
Lagarde CB, Thapa K, Cullen NM, Hawes ML, et al · · 2024 · cited 7× · PMID 39439572 · DOI 10.3389/fendo.2024.1465727

Verify or expand the search:

Other trials of Axitinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06161558 — Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors · Phase 1 · withdrawn
NCT06690697 — Combination of Toripalimab and JS004 Therapy for ccRCC · Phase 2 · recruiting
NCT05176288 — Avelumab, Palbociclib and Axitinib in Advanced RCC · Phase 2 · withdrawn

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Lynkcell Europe trials

Trials by the same sponsor.

NCT05941637 — An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05904730 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lynkcell Europe
Last refreshed: 30 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05904730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing